Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Apolipoprotein E ɛ4 allele is a common susceptibility gene for late-onset Alzheimer's disease. Brain vascular and metabolic deficits can occur in cognitively normal apolipoprotein E ɛ4 carriers decades before the onset of Alzheimer's disease. The goal of this study was to determine whether early intervention using rapamycin could restore neurovascular and neurometabolic functions, and thus impede pathological progression of Alzheimer's disease-like symptoms in pre-symptomatic Apolipoprotein E ɛ4 transgenic mice. Using in vivo, multimodal neuroimaging, we found that apolipoprotein E ɛ4 mice treated with rapamycin had restored cerebral blood flow, blood–brain barrier integrity and glucose metabolism, compared to age- and gender-matched wild-type controls. The preserved vasculature and metabolism were associated with amelioration of incipient learning deficits. We also found that rapamycin restored the levels of the proinflammatory cyclophilin A in vasculature, which may contribute to the preservation of cerebrovascular function in the apolipoprotein E ɛ4 transgenics. Our results show that rapamycin improves functional outcomes in this mouse model and may have potential as an effective intervention to block progression of vascular, metabolic and early cognitive deficits in human Apolipoprotein E ɛ4 carriers. As rapamycin is FDA-approved and neuroimaging is readily used in humans, the results of the present study may provide the basis for future Alzheimer's disease intervention studies in human subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Nonoxidative Glucose Consumption During Focal Physiologic Neural Activity
Fox, P. T., Raichle, M. E., Mintun, M. A., & Dence, C. (1988) · Science · doi:10.1126/science.3260686 · Cited by 1,796
Eichenbaum (2004) · doi:10.1016/j.neuron.2004.08.028 · Cited by 1,464 · cited 1×
“25 In line with this, we observed a transient but significant delay in learning difficulty in the MWM in the APOE4-control mice, though it was overcome with repeated training.”
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 4×
“8 CypA causes BBB breakdown by activating the NF-k B-matrix-metallo-proteinase-9 (MMP9) pathway.”
InfluentialSpilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033 · cited 2×
“APOE4-control animals, however, showed significantly increased latencies on day 2 compared to all other experimental groups (Figure 4(a)), a behavioral pattern common to other mouse models of AD 12,13,21 and suggestive of delayed learning.”
Self-citationClinical epidemiology of Alzheimer’s disease: assessing sex and gender differences
Mielke, M., Vemuri, P., & Rocca, W. (2014) · Clinical Epidemiology · doi:10.2147/clep.s37929 · Cited by 1,021
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 2×
“4,5,7 As glucose metabolism is highly associated with neuronal activity, 24 our results indicate that the APOE4 mice displayed both neuronal and synaptic dysfunctions, consistent with previous reports.”
mTOR inhibition improves immune function in the elderly
Mannick, J. B., Del Giudice, G., Lattanzi, M., Valiante, N. M., Praestgaard, J., Huang, B., Lonetto, M. A., Maecker, H. T., Kovarik, J., Carson, S., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009892 · Cited by 786 · cited 3×
“Mannick et al. 45 reported that low doses of rapamycin significantly improved immune functions in the elderly with minimal side effects.”
Influential
Research works printed but not linked: 30
- 10.1126/science.8346443 · DOI · Paper page
- 10.1001/archneurol.2009.913 · DOI · Paper page
- 10.1073/pnas.0500579102 · DOI · Paper page
- 10.3233/JAD-2011-0010 · DOI · Paper page
- 10.1038/jcbfm.2014.172 · DOI · Paper page
- 10.1038/jcbfm.2013.82 · DOI · Paper page
- 10.3233/JAD-2011-110479 · DOI · Paper page
- 10.1042/BJ20140291 · DOI · Paper page
- 10.3233/JAD-148007 · DOI
- 10.2217/bmm.14.42 · DOI
- 10.1016/j.neurobiolaging.2015.03.012 · DOI · Paper page
- Halliday MR, J Cereb Blood Flow Metab
- 10.1038/nm0497-421 · DOI · Paper page
- Lin AL, 2010, Front Neuroenergetics, 2, 1
- 10.1038/jcbfm.2014.114 · DOI · Paper page
- 10.1523/JNEUROSCI.0671-06.2006 · DOI · Paper page
- 10.1038/jcbfm.2008.62 · DOI · Paper page
- 10.1016/j.nut.2010.07.021 · DOI · Paper page
- 10.1111/j.1749-6632.1997.tb48479.x · DOI · Paper page
- 10.1016/S0197-4580(00)00130-5 · DOI
- 10.3233/JAD-2011-110899 · DOI · Paper page
- 10.1038/jcbfm.2013.116 · DOI
- 10.1155/2012/907409 · DOI
- 10.2217/fnl.14.13 · DOI
- 10.1002/mrm.22667 · DOI
- 10.1007/s11523-011-0174-9 · DOI
- Hurez V, Aging Cell
- 10.1007/s11523-011-0178-5 · DOI
- Mita MM, 2003, Cancer Biol Therapy, 2, S169
- 10.1016/j.exger.2014.12.002 · DOI · Paper page
Cited by
Ungvari, Z., Tarantini, S., Donato, A. J., Galvan, V., & Csiszar, A. (2018) · Circulation Research · doi:10.1161/circresaha.118.311378 · Cited by 919
Metabolic Control of Longevity
López-Otín, C., Galluzzi, L., Freije, J. M. P., Madeo, F., & Kroemer, G. (2016) · Cell · doi:10.1016/j.cell.2016.07.031 · Cited by 753
Endothelial dysfunction and angiogenesis impairment in the ageing vasculature
Ungvari, Z., Tarantini, S., Kiss, T., Wren, J. D., Giles, C. B., Griffin, C. T., Murfee, W. L., Pacher, P., & Csiszar, A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0030-z · Cited by 473
The quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
Targeting the biology of aging with mTOR inhibitors
Mannick, J. B., & Lamming, D. W. (2023) · Nature Aging · doi:10.1038/s43587-023-00416-y · Cited by 372
Metadata
- Authors
- Lin, A.-L., Jahrling, J. B., Zhang, W., DeRosa, N., Bakshi, V., Romero, P., Galvan, V., & Richardson, A.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2016-07-22
- Volume
- 37
- Issue
- 1
- Pages
- 217-226
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2289353571
- Cited by
- 155
- References
- 19
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease. https://app.cochat.ai/papers/10.1177/0271678x15621575
- The paper
- Lin, A.-L., Jahrling, J. B., Zhang, W., DeRosa, N., Bakshi, V., Romero, P., Galvan, V., & Richardson, A. (2017). Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease. Journal of Cerebral Blood Flow & Metabolism. https://doi.org/10.1177/0271678x15621575
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.